Exp Mol Med.
2015 Aug;47(8):e176. 10.1038/emm.2015.43.
Prognostic role of genetic biomarkers in clinical progression of prostate cancer
- Affiliations
-
- 1Laboratory of Genetic Identification, Faculty of Medicine, Legal Medicine and Toxicology Department, University of Granada, Granada, Spain. mjesusac@ugr.es
- 2GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Granada, Spain.
- 3Service of Urology, University Hospital Virgen de las Nieves, Granada, Spain.
- KMID: 2155430
- DOI: http://doi.org/10.1038/emm.2015.43
Abstract
- The aim of this study was to analyze the use of 12 single-nucleotide polymorphisms in genes ELAC2, RNASEL and MSR1 as biomarkers for prostate cancer (PCa) detection and progression, as well as perform a genetic classification of high-risk patients. A cohort of 451 men (235 patients and 216 controls) was studied. We calculated means of regression analysis using clinical values (stage, prostate-specific antigen, Gleason score and progression) in patients and controls at the basal stage and after a follow-up of 72 months. Significantly different allele frequencies between patients and controls were observed for rs1904577 and rs918 (MSR1 gene) and for rs17552022 and rs5030739 (ELAC2). We found evidence of increased risk for PCa in rs486907 and rs2127565 in variants AA and CC, respectively. In addition, rs627928 (TT-GT), rs486907 (AG) and rs3747531 (CG-CC) were associated with low tumor aggressiveness. Some had a weak linkage, such as rs1904577 and rs2127565, rs4792311 and rs17552022, and rs1904577 and rs918. Our study provides the proof-of-principle that some of the genetic variants (such as rs486907, rs627928 and rs2127565) in genes RNASEL, MSR1 and ELAC2 can be used as predictors of aggressiveness and progression of PCa. In the future, clinical use of these biomarkers, in combination with current ones, could potentially reduce the rate of unnecessary biopsies and specific treatments.
MeSH Terms
-
Aged
Aged, 80 and over
Cohort Studies
Disease Progression
Endoribonucleases/*genetics
Gene Frequency
Genetic Markers/genetics
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Neoplasm Proteins/*genetics
*Polymorphism, Single Nucleotide
Prognosis
Prostate/metabolism/*pathology
Prostatic Neoplasms/*diagnosis/*genetics
Scavenger Receptors, Class A/*genetics
Endoribonucleases
Genetic Markers
Neoplasm Proteins
Scavenger Receptors, Class A
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pathogenesis of Prostate Cancer
- Clinically relevant genetic characterization of prostate tumors: How close are we to the goal?
- Clinical Utility of Novel Biomarkers in the Era of Active Surveillance of Prostate Cancer
- Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
- Potential Epigenetic Biomarkers for Prostate Cancer Screening
